1. Home
  2. CRSP vs PHI Comparison

CRSP vs PHI Comparison

Compare CRSP & PHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$56.70

Market Cap

5.6B

Sector

Health Care

ML Signal

HOLD

PHI

PLDT Inc. Sponsored ADR

HOLD

Current Price

$21.46

Market Cap

4.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
PHI
Founded
2013
1928
Country
Switzerland
Philippines
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
4.7B
IPO Year
2016
1953

Fundamental Metrics

Financial Performance
Metric
CRSP
PHI
Price
$56.70
$21.46
Analyst Decision
Buy
Hold
Analyst Count
19
1
Target Price
$71.50
N/A
AVG Volume (30 Days)
1.8M
62.8K
Earning Date
02-10-2026
11-11-2025
Dividend Yield
N/A
5.67%
EPS Growth
N/A
9.36
EPS
N/A
2.32
Revenue
$38,337,000.00
$3,761,997,877.00
Revenue This Year
N/A
$2.70
Revenue Next Year
$723.84
$2.64
P/E Ratio
N/A
$9.22
Revenue Growth
N/A
1.69
52 Week Low
$30.04
$18.61
52 Week High
$78.48
$25.12

Technical Indicators

Market Signals
Indicator
CRSP
PHI
Relative Strength Index (RSI) 51.43 49.68
Support Level $54.50 $21.04
Resistance Level $59.18 $22.16
Average True Range (ATR) 2.87 0.34
MACD 0.33 -0.15
Stochastic Oscillator 44.03 36.48

Price Performance

Historical Comparison
CRSP
PHI

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About PHI PLDT Inc. Sponsored ADR

PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.

Share on Social Networks: